Asad Haider
Stock Analyst at Goldman Sachs
(2.80)
# 1,612
Out of 5,173 analysts
15
Total ratings
71.43%
Success rate
17.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $88.41 | +60.62% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $235.42 | +1.95% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $30.01 | +23.29% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $57.00 | - | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $21.91 | -22.41% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $45.61 | -7.91% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $55.94 | -32.07% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $910.55 | -2.48% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $204.93 | -5.33% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $26.77 | -6.61% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $88.41
Upside: +60.62%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $235.42
Upside: +1.95%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $30.01
Upside: +23.29%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $57.00
Upside: -
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $21.91
Upside: -22.41%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $45.61
Upside: -7.91%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $55.94
Upside: -32.07%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $910.55
Upside: -2.48%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $204.93
Upside: -5.33%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $26.77
Upside: -6.61%